Discontinued — last reported Q4 '23
Products & Services · Research and development expense
Mosunetuzumab — Research and development expense
Biogen Mosunetuzumab — Research and development expense remained flat by 0.0% to $7.10M in Q4 2023 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $7.10M to $7.10M.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2023
Rolls up toR&D
How to read this metric
Increasing expenses may signal active clinical progression or late-stage trial intensity, while decreasing expenses may indicate project completion or strategic reprioritization.
Detailed definition
Captures the total costs incurred for research and development activities specifically attributable to a single product...
Peer comparison
Standard R&D reporting across the biopharmaceutical industry, often categorized by therapeutic area or specific drug program.
Metric ID:
biib_segment_mosunetuzumab_research_and_development_expenseHistorical Data
2 years
| FY'22 | FY'23 | |
|---|---|---|
| Value | $28.40M | $28.40M |
| YoY Change | — | +0.0% |
Range$28.40M – $28.40M
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's mosunetuzumab — research and development expense?
- Biogen (BIIB) reported mosunetuzumab — research and development expense of $7.10M in Q4 2023.
- How has Biogen's mosunetuzumab — research and development expense changed year-over-year?
- Biogen's mosunetuzumab — research and development expense decreased by 0.0% year-over-year, from $7.10M to $7.10M.
- What does mosunetuzumab — research and development expense mean?
- Total spending dedicated to the research and development of a specific drug candidate.